BIOGEN INC (BIIB) Stock Analyst Ratings
USA - NASDAQ:BIIB - US09062X1037 - Common Stock
168.57 USD
+3.84 (+2.33%)
ChartMill assigns a Buy % Consensus number of 74% to BIIB. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 175.03. This target is 3.83% above the current price.
BIIB was analyzed by 42 analysts. The buy percentage consensus is at 74. So analysts seem to be have mildly positive about BIIB.
In the previous month the buy percentage consensus was at a similar level.
BIIB was analyzed by 42 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-06 | Stifel | Upgrade | Hold -> Buy |
| 2025-11-03 | Bernstein | Maintains | Market Perform -> Market Perform |
| 2025-10-31 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-10 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-09-25 | Jefferies | Initiate | Buy |
| 2025-09-24 | Needham | Reiterate | Hold -> Hold |
| 2025-09-04 | Needham | Reiterate | Hold -> Hold |
| 2025-08-14 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-08-01 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-01 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-08-01 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-08-01 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-06-27 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-06-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-25 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-06-12 | Needham | Reiterate | Hold -> Hold |
| 2025-06-12 | Wedbush | Reiterate | Neutral -> Neutral |
| 2025-06-12 | Piper Sandler | Reiterate | Neutral -> Neutral |
| 2025-05-07 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-05-05 | JP Morgan | Maintains | Neutral -> Neutral |
| 2025-05-02 | Needham | Reiterate | Hold -> Hold |
| 2025-05-02 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-02 | Baird | Maintains | Outperform -> Outperform |
| 2025-05-02 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-05-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-04-29 | Truist Securities | Maintains | Buy -> Buy |
| 2025-04-29 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-04-25 | Needham | Reiterate | Hold -> Hold |
| 2025-04-23 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-04-22 | RBC Capital | Maintains | Outperform -> Outperform |
BIOGEN INC / BIIB FAQ
What do analysts expect the price target to be for BIOGEN INC (BIIB)?
42 analysts have analysed BIIB and the average price target is 175.03 USD. This implies a price increase of 3.83% is expected in the next year compared to the current price of 168.57.
Can you provide the consensus rating for BIOGEN INC stock?
The consensus rating for BIOGEN INC (BIIB) is 73.8095 / 100 . This indicates that analysts generally have a positive outlook on the stock.